The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

William R. Hiatt

Section of Vascular Medicine

Division of Geriatrics

University of Colorado Denver School of Medicine

Denver

USA

[email]@uchsc.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Section of Vascular Medicine, Division of Geriatrics, University of Colorado Denver School of Medicine, Denver, USA. 2001 - 2010
  • University of Colorado Denver, School of Medicine, Denver, CO 80203, USA. 2008

References

  1. Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. Hiatt, W.R., Hirsch, A.T., Creager, M.A., Rajagopalan, S., Mohler, E.R., Ballantyne, C.M., Regensteiner, J.G., Treat-Jacobson, D., Dale, R.A., Rooke, T. Vasc. Med (2010) [Pubmed]
  2. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). Hiatt, W.R., Money, S.R., Brass, E.P. J. Vasc. Surg. (2008) [Pubmed]
  3. Acute pharmacological conversion of atrial fibrillation to sinus rhythm: is short-term symptomatic therapy worth it? A report from the December 2007 Meeting of the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration. Hiatt, W.R., Lincoff, A.M., Harrington, R.A. Circulation (2008) [Pubmed]
  4. New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, Md. Hiatt, W.R., Nissen, S.E. Circulation (2006) [Pubmed]
  5. Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication. Hiatt, W.R., Krantz, M.J. Vasc. Med (2006) [Pubmed]
  6. Quality of the assessment of primary and secondary endpoints in claudication and critical leg ischemia trials. Hiatt, W.R., Cox, L., Greenwalt, M., Griffin, A., Schechter, C. Vasc. Med (2005) [Pubmed]
  7. The US experience with cilostazol in treating intermittent claudication. Hiatt, W.R. Atheroscler. Suppl (2005) [Pubmed]
  8. Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy. Hiatt, W.R., Hirsch, A.T., Cooke, J.P., Olin, J.W., Brater, D.C., Creager, M.A. Vasc. Med (2004) [Pubmed]
  9. Treatment of disability in peripheral arterial disease: new drugs. Hiatt, W.R. Curr. Drug. Targets. Cardiovasc. Haematol. Disord (2004) [Pubmed]
  10. Carnitine and peripheral arterial disease. Hiatt, W.R. Ann. N. Y. Acad. Sci. (2004) [Pubmed]
  11. The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease. Hiatt, W.R., Klepack, E., Nehler, M., Regensteiner, J.G., Blue, J., Imus, J., Criqui, M.H. Vasc. Med (2004) [Pubmed]
  12. Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy. Hiatt, W.R. J. Intern. Med. (2002) [Pubmed]
  13. Pharmacologic therapy for peripheral arterial disease and claudication. Hiatt, W.R. J. Vasc. Surg. (2002) [Pubmed]
  14. Medical treatment of peripheral arterial disease and claudication. Hiatt, W.R. N. Engl. J. Med. (2001) [Pubmed]
 
WikiGenes - Universities